The promise of cell and gene therapies is big. They have the ability to address the underlying genetic causes of disease, offering new possibilities for people with serious and previously difficult-to-treat conditions. But as cell and gene therapies move beyond [See the full post…]

With recent innovation and policy movement related to the pharmaceutical supply chain, are we on the verge of demonstrable change that will promote greater transparency and affordability for prescription drugs? On this episode of the Business Group on Health podcast, [See the full post…]